LONDON, March 27, 2015 /PRNewswire/ --
Richmond Pharmacology enrols first patient Worldwide
Working in collaboration with the National Amyloidosis Centre at the Royal Free Hospital in London, Richmond Pharmacology is the first centre worldwide to dose a patient for a global Phase 3 study for an investigational RNAi therapeutic being developed for the treatment of transthyretin-mediated amyloidosis (ATTR), an orphan disease affecting the nerves and heart.
Based at St Georges University of London, Richmond Pharmacology is one of 15 MHRA accredited UK phase one units with a database of just under 200,000 registered and pre-qualified volunteers willing to participate clinical trials. Our extensive metrics and feasibility assessments offer sponsors invaluable insight into study acceptability and suitability of the target population, ensuring accurate predictability of recruitment time and attrition rates. As a result we meet all our recruitment targets just as we say, with no extensions and no extra costs. For contact and enquiries visit http://www.richmondpharmacology.com
DR Jorg Taubel
SOURCE Richmond Pharmacology Ltd